GeneDx (WGS) Announces Preliminary 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
GeneDx Announces Preliminary 2024 Financial Results
January 13, 2025 8:30 AM ESTExpects to exceed guidance with full year 2024 revenues1 of at least $299 million
Expects fourth quarter 2024 revenues1 of at least $92 million
Expects to exceed guidance with full year 2024 adjusted gross margin1 of at least 64%
Expects fourth quarter 2024 adjusted gross margin1 of at least 68%
STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2024.
2024... More
